Clinical Trials Logo

Bile Duct Diseases clinical trials

View clinical trials related to Bile Duct Diseases.

Filter by:

NCT ID: NCT00840138 Active, not recruiting - Cholecystectomy Clinical Trials

A Comparison of Bile Duct Injuries Following Open Cholecystectomy Versus Laparoscopic Cholecystectomy

Start date: January 1996
Phase: N/A
Study type: Observational

In this prospective study the investigators compared common bile duct injuries (CBDI) following laparoscopic cholecystectomy (LC) and open cholecystectomy (OC) procedures, 35 patients in each group. To date, no detailed study concerning this matter has been published. LC - CBDI in comparison with OC - CBDI more often concerned young females with a narrow CBD, they were located closer to the liver hilus, and they were more extended.

NCT ID: NCT00731198 Completed - Pancreatic Diseases Clinical Trials

Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP)

Start date: August 2008
Phase: Phase 3
Study type: Interventional

The aim of the present study was to evaluate the use of drotaverine hydrochloride versus hyoscine-N-butylbromide in reducing duodenal motility during diagnostic and therapeutic ERCP.

NCT ID: NCT00270868 Active, not recruiting - Bile Duct Diseases Clinical Trials

Efficacy of Double Wire Technique in Difficult Cases of Common Bile Duct Cannulation in ERCP (UDOGUIA-04)

Start date: November 2004
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the double guide wire technique is more effective than the conventional method in those cases of difficult selective biliary cannulation in the ERCP procedures.

NCT ID: NCT00040131 Terminated - Pancreatitis Clinical Trials

Safety and Efficacy Study of IL-10 (Tenovil TM) in the Prevention of Post-ERCP Acute Pancreatitis (Study P02580)(TERMINATED)

Start date: January 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if a single dose of IL-10 compared to placebo is safe and effective in reducing the incidence of post-ERCP acute pancreatitis for subjects with increased risk.